Accessibility Menu
 
Carisma Therapeutics logo

Carisma Therapeutics

(OTC) CARM

Current Price$0.00
Market Cap$20,900
Since IPO (2023)-100%
5 Year-100%
1 Year-100%
1 Month-99%

Carisma Therapeutics Financials at a Glance

Market Cap

$20,900

Revenue (TTM)

$52.63M

Net Income (TTM)

$8.04M

EPS (TTM)

$0.19

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

3.33 (High)

Price

$0.00

Volume

9,907

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $1.27

CARM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Carisma Therapeutics

Industry

Biotechnology

Employees

46

CEO

Steven Kelly, MBA

Headquarters

Philadelphia, PA 19104, US

CARM Financials

Key Financial Metrics (TTM)

Gross Margin

98%

Operating Margin

21%

Net Income Margin

15%

Return on Equity

0%

Return on Capital

-42%

Return on Assets

1%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.90K

Shares Outstanding

41.85M

Volume

9.91K

Avg. Volume

75.82K

Financials (TTM)

Gross Profit

$40.04M

Operating Income

$62.18M

EBITDA

$56.83M

Operating Cash Flow

$59.92M

Capital Expenditure

$123.00K

Free Cash Flow

$60.04M

Cash & ST Invst.

$18.83M

Total Debt

$2.48M

Carisma Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$45.25M

+1236.8%

Gross Profit

$45.25M

+1236.8%

Gross Margin

100.00%

N/A

Market Cap

$20.90K

N/A

Market Cap/Employee

$454.35

N/A

Employees

46

N/A

Net Income

$44.72M

+452.0%

EBITDA

$44.72M

+460.4%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Net Cash

$2.02M

-91.4%

Accounts Receivable

$1.64M

N/A

Inventory

$0.00

N/A

Long Term Debt

$609.00K

-28.9%

Short Term Debt

$153.00K

-93.8%

Return on Assets

1.23%

N/A

Return on Invested Capital

-42.04%

N/A

Free Cash Flow

$1.91M

+114.7%

Operating Cash Flow

$1.91M

+114.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLXNSilexion Therapeutics Ltd.
$0.60-2.25%
CDTCDT Equity Inc.
$2.26-2.80%
SPRCSciSparc Ltd.
$7.91-9.81%
ASBPAspire Biopharma Holdings, Inc.
$0.21-4.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$13.30+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07+0.05%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.70+0.01%
SOFISoFi Technologies
$16.43+0.02%

Questions About CARM

What is the current price of Carisma Therapeutics?

Carisma Therapeutics is trading at $0.00 per share.

What is the 52-week range for Carisma Therapeutics?

Over the past 52 weeks, Carisma Therapeutics has traded between $0.00 and $1.27.

How much debt does Carisma Therapeutics have?

As of the most recent reporting period, Carisma Therapeutics reported total debt of $762,000.

How much cash does Carisma Therapeutics have on hand?

Carisma Therapeutics reported $2.78M in cash and cash equivalents in its most recent financial results.

What is Carisma Therapeutics’s dividend yield?

Carisma Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.